Director, DMPK
Listed on 2026-09-18
-
Science
Pharmaceutical Science/ Research, Drug Discovery, Research Scientist, Data Scientist
About Evommune, Inc.
Evommune, Inc. is a private clinical-stage biotechnology company dedicated to revolutionizing the treatment of immune-mediated inflammatory diseases. Founded in 2020 by a leading team of R&D experts and biotech innovators, Evommune is headquartered in Palo Alto, California, with additional offices in New York, NY. Through groundbreaking science, we are committed to discovering, developing, and delivering therapies that not only address symptoms but also halt disease progression.
Our pipeline focuses on advancing novel treatment options for underserved patient populations, targeting diseases at their root with best-in-class agents for safety and efficacy. For more information, visit
This hybrid position is currently expected to be in the office 2 days a week with the option of working remotely 3 days a week. The position reports to the Executive Director, Non-Clinical Development. This is a unique opportunity to join an innovative biotech developing novel therapeutics for chronic inflammatory diseases. Evommune’s pipeline is focused on advancing new treatment options in underserved patient populations.
We target these pathologies at the source, with novel agents that exhibit best-in-class profiles for safety and efficacy, delivering therapeutics for patients that go beyond symptomatic relief.
- Together We Win:
We champion teamwork, celebrating every achievement as a shared success. - Guided by Insight:
We make data-driven decisions, using our collective experience to shape the future of our business. - Every Day Matters:
We act with urgency to bring transformative therapies to patients by being nimble, decisive, and effective. - Driven By Excellence:
We set a high bar and hold ourselves accountable to deliver exceptional results in everything we do.
Empowered To Act:
We invest in our team and value transparency, fostering trust and a sense of ownership.
We seek individuals who resonate with these principles, as they are essential for thriving in our collaborative, innovative, and dynamic work environment.
About the roleAs the Director of DMPK, you will be responsible for providing scientific and technical leadership in ADME/PK/PK-PD strategy for small molecules to support drug discovery and development. You will lead critical DMPK efforts from discovery through clinical development, including first-in-human (FIH) dose predictions and preparation of regulatory documents. This role requires exceptional scientific expertise, collaboration skills, and the ability to influence decision-making to advance our programs.
We are looking for a strong leader with a proven track record, excellent problem-solving capabilities, and a commitment to quality to shape and drive the DMPK strategy. If you thrive in a hands-on, innovative environment, we want to hear from you.
What you'll do- Provide expert technical and scientific leadership in pharmacokinetics, pharmacodynamics, drug metabolism, and bioanalytical methodologies.
- Develop and implement DMPK and PK-PD strategies that align with Evommune’s drug discovery and development objectives.
- Serve as DMPK lead on cross-functional discovery and development project teams.
- Collaborate with internal teams, including medicinal chemistry, pharmacology, toxicology, clinical, and CMC, to support program progression.
- Design, execute, and interpret DMPK studies, ensuring timely communication of results to project teams, senior leadership, and external stakeholders.
- Oversee relationships with CROs, consultants, and external partners to enhance DMPK resources and capabilities.
- Author or contribute to DMPK sections of regulatory filings (e.g., IND, CTA), ensuring compliance with global regulatory guidelines.
- Provide FIH dose projections and guide…
(If this job is in fact in your jurisdiction, then you may be using a Proxy or VPN to access this site, and to progress further, you should change your connectivity to another mobile device or PC).